In this article, we review the evidence suggesting a possible role for B19 virus in the pathogenesis of a subset of cases of acute leukemia. Human parvovirus B19 infection may complicate the clinical course of patients with acute leukemia, and may also precede the development of acute leukemia by up to 180 days. Parvovirus B19 targets erythroblasts in the bone marrow, and may cause aplastic crisis in patients with shortened red cell survival. Aplastic crisis represents a prodrome of ALL in 2% patients. There is significant overlap between those HLA class I and II alleles which are associated with a vigorous immune response and development of symptoms during B19 infection, and those HLA alleles which predispose to development of acute leukemia. Acute symptomatic B19 infection is associated with low level of circulating IL-10 consistent with a vigorous immune response; deficient IL-10 production at birth was recently found to be associated with subsequent development of acute leukemia. Anti-B19 IgG has been associated with a particular profile of methylation of human cancer genes in patients with acute leukemia, suggesting an additional hit and run mechanism. The proposed role for parvovirus B19 in the pathogenesis of acute leukemia fits very well with the delayed infection hypothesis and with the 2-step mutation model, which describes the carriage of the first mutation prior to birth, followed by suppression of haematopoiesis, which allows rapid proliferation of cells harbouring the first mutation, acquisition of a second activating mutation, and expansion of cells carrying both mutations, resulting in a clinical presentation of acute leukemia.
Introduction
Acute childhood leukemia accounts for most cases of childhood cancer and its cause, or causes, are not yet understood, although modern treatment regimens are often successful. Many candidate environmental exposures have been proposed, however, most of these lack epidemiological evidence and plausible biological mechanisms. Significant evidence supports the role of infection and immunity in the pathogenesis of acute childhood leukemia, however, it is not clear whether one or more infectious agents are involved [1] .
Human parvovirus B19 is a single-stranded DNA virus which replicatesprimarily in the erythroblasts in the bone marrow and it has been shown to persist life-long in many different cell types throughout the body following acute infection [2] . B19 infection commonly causes erythema infectiosum, arthralgia, fetal death, transient aplastic crisis in patients with shortened red cell survival, and persistent infection in immunocompromised persons. Less common clinical manifestations include atypical skin rashes, neurological syndromes, cardiac syndromes, and various cytopenias resulting from bone marrow infection [2, 3] .
B19 infection has also been demonstrated to occur in the setting of acute leukemia. This has been thought to represent either reactivation of latent B19 virus due to immunosuppression or due to coincidental acquisition of B19 virus in the context of acute leukemia during cytotoxic treatment. But more interestingly, there have been a significant number of case reports of acute leukemia with documented acute B19 infection occurring either before or at the time of diagnosis of acute leukemia, suggesting the possibility that B19 virus may contribute to the pathogenesis of acute leukemia in some way.
In this review, we review all published cases of B19 infection associated with acute leukemia, occurring both before and after the diagnosis of acute leukemia, studies of B19 infection in leukemia, parallels between the pathogenesis of acute leukemia and that of B19 infection, the particular features of B19 infection which highlight its potential as a candidate trigger infection in the pathogenesis of acute leukemia, consideration of other childhood virus infections which have been associated with acute leukemia, and recommendations for future research. Table 1 summarises the clinical course of 29 patients with acute leukemia in whom B19 infection was documented during chemotherapy. The age range of these patients was 1 -65 years, with 13 males, 15 females and one of unknown sex. There were 17 patients with acute lymphoblastic leukemia (ALL), 2 patients with B cell ALL, 6 patients with pre-BALL, one patient with acute myeloblastic leukemia (AML) type M6b, 2 patients with LGLL and one patient with CTCL. The interval between diagnosis of leukemia and onset of B19 infection ranged from 14 days to 14 years. B19 infection resulted in some degree of anemia in all patients, which ranged from mild to severe; thrombocytopenia was documented in 13 patients, lymphocytopenia in one patient and neutropenia in 2 patients. B19 infection was not treated in 5 patientsand treatment was undisclosed for 2 patients. Five patients received intravenous immunoglobulin (IVIG) alone, while 8 patients received both IVIG and red cell transfusion. Five patients received red cell transfusion alone, while 3 patients were treated by stopping chemotherapy. There were no deaths due to B19 infection and all patients recovered with or without specific treatment.
Case reports of B19 infection in patients with acute leukemia during chemotherapy
the diagnosis of leukemia.Detection of B19 infection in the remaining 9 patients without a prodrome of aplastic crisis, occurred 0 -3 days before the diagnosis of acute leukemia. All 16patients except one (No. 3) had anemia at presentation, which ranged from mild to severe. Patient no. 3 also stands out as having a different clinical presentation from the others, in that this was the only patient to present with neurological symptoms.
Evidence of acute B19 infection at presentation consisted of detection of either anti-B19 IgM or DNA, or both, except in the case of patient no. 10, who did not have specific B19 testing performed.However, this case had a prodrome of aplastic crisis, a rash resembling erythema infectiosum, anemia, erythroid hypoplasia on bone marrow testing, and other presenting symptoms typical of B19 infection. Bone marrow was examined in 13 of 16 cases, and each of these 13patientsexhibited at least one of the following recognized signs of B19 infection; erythroid hypoplasia, pancytopenia and giant pronormoblasts. Regarding treatment for B19 infection, 4 patients received red cell transfusion, 4 patients received both platelet and red cell transfusions, one patient received IVIG alone and 7 patients received no treatment. In 3 cases, outcome was not stated; among the remaining 13 patients, there were 4 deaths which were due to relapse (n=1), secondary bacterial sepsis (n=2), and idiopathic pneumonia syndrome (n=1). The remaining 9 patients recovered. Table 3 summarises the results of various studies of B19 infection in acute leukemia. Where sufficient clinical details were included in these reports, specific patients were included in either Table 1 or Table 2, as appropriate.
Studies of B19 infection in acute leukemia
Broliden et al [18] tested the bone marrow of 59 unselected children with malignancies by PCR to detect B19 DNA; 7 of 59 were positive, consisting ofALL on chemotherapy (n=3) (in one of these 3 cases, the presence of B19 was not associated with symptoms; the other two cases have been included in Table 1 as patient numbers 7 (n=1). Unfortunately, the total number of cases within each disease category of childhood malignancies was not available.
El-Mahallawy et al [35] tested 50 ALL patients with anemia and 34 ALL patients without anemia (both groups were on maintenance therapy) for evidence of B19 infection. B19 DNA was positive in 11 of 50 ALL with anemia (of which, 4 were IgM+) compared with 2 of 34 ALL without anemia (none were serum anti-B19 IgM positive). and found none positive; one ALL patient was found to be positive for B19 DNA 5 months prior to diagnosis of ALL during an episode of pancytopenia. This case report has been reported in detail [32] and is included as patient no. 14 in Table 2 .
Heegaard et al [43] As regards the interpretation of these studies, as B19 virus persists indefinitely in various tissues, including blood and bone marrow, following acute infection, the clinical significance of detection of B19 DNA in the absence of recognised B19-associated symptoms is not entirely clear. This is quite a different situation to the detection of B19 DNA in blood contemporaneous with the occurrence of B19-associated symptoms, such as aplastic crisis or erythema infectiosum, in those patients included in Table 2 , for example, in which sufficient clinical data is provided to enable confirmation that the clinical course of each patient was significantly impacted by acute B19 infection.
The pathogenesis of acute leukemia
A significant body of research supports the role of infection in the pathogenesis of acute childhood leukemia, and especially ALL. There are two main proposed infectious pathogenetic mechanisms which overlap somewhat. First, that childhood leukemia may result from infection with a specific infectious agent introduced into a population without herd immunity [47] . And second, that delayed exposure to common infections during infancy and childhood results in an increased risk of common pre-B cell ALL in children who harbor genetic mutations that result in the creation of a leukemic clone [48] . Such clones may then proliferate and expand into ALL upon stimulation with infections that occur later, some time after birth. Although there are many reports which support both of these hypotheses, there have been few proposed specific molecular mechanisms [1] . This sequence is summarized diagrammatically in Figure 1 .
A significant body of evidence supports the second hypothesis of Greaves [48] , including epidemiological studies which used surrogate indicators of exposure to infections, including birth order, history of infections in individuals, attendance at day-care and play groups, and parental contacts with possible sources of infection in the workplace [49, 50] . These studies have shown that reduced exposure in early life to common childhood infections, increases the risk of developing leukemia. It has been shown that population mixing is an important risk factor, which further strengthens the putative role for infection in the causation of childhood leukemia. It is hypothesized that delayed infection during infancy may be an important causal factor [1] .
There are a few recorded clusters of childhood leukemia [50] [51] [52] , however, the role of time-space clustering appears to be modest [50, 51, 53, 54] .
There have been numerous studies of HLA associations in childhood acute leukemia [55] . Various class II HLA alleles have been shown to be risk factors for development of childhood acute leukemia, including HLA-DPB1*0201 [56] and HLA-DR53, which is linked to carriage of HLA-DRB1*04, *07 and *09 alleles [57] . The supertypic specificity HLA-DR53 is encoded by theHLA-DRB4 locus in the HLA class II region. There was a moderate allelic association with the most common allele in the HLA-DR53 group, HLA-DRB1*04, in the whole group that was stronger in males [57] . HLA-DRB1*15 and *16 have also been reported as predisposing alleles [58, 59] and also HLA-DRB1*01 [60] . Interestingly, ancestral HLA analysis has shown that there are 2 clades regarding the HLA-DR gene polymorphisms, and that DRB1*01, *04, *07, *09, *15, and *16 are grouped with DR4 and DR5, while DRB1*03, *08, *11, *12, *13 and *14 are grouped with DR3 [61] . Interestingly, HLA-DRB1 alleles *01, *04, *07, *09, *15, and *16 have a net positive charge within the first hypervariable region, while HLA-DRB1 alleles *03, *08, *11, *12, *13 and *14 have a net negative charge within this region. The significance of this is considered below.
Class I HLA associations with acute leukemia include HLA-B40 [62] , HLA-A11, HLA-B38 and HLA-B49 [63] . Klitz et al [64] report a continuum of risk associations for HLA-A, HLA-B and HLA-DRB1,supporting the hypothesis that infection and the resulting immune response, is important in the pathogenesis of acute leukemia.
Recently, it has been shown that interleukin-10 secretion is severely deficient in children who grow up to develop leukemia [65] . IL-10 is a strong anti-inflammatory cytokine secreted by monocytes and lymphocytes and is important in the limitation of cell-mediated immune reactions.It has been shown that IL-10 production attenuated an increased risk for repeated respiratory infections during infancy and childhood associated with elevated T cell IL-5 production at birth [66] .It is possible that children with dysregulated immunefunction at birth are at higher risk for developing leukemia due to constitutively lowerexpression of IL-10, a cytokine that attenuates inflammatory responses [67] .
Several studies and case reports indicate that asmall sub-group of ALL patientsundergo a previous phase of aplasia, which precedes development of overt ALL by 2-9 months [68, 69] . This is almost always associated with infection and either remits spontaneously or responds to corticosteroids. In the few cases that have been studied, immunoglobulin or T cell receptor gene analysis have confirmed the presence of the leukemia, or preleukemic, cells during this aplastic phase [70, 71] .
Pathogenesis of parvovirus B19 infection
The pathogenesis of parvovirus B19 infection is complex, particularly when the less common clinical manifestations are included. Although the mechanisms are considered separately, clearly they donot occur separately in vivo, and during a single B19 infection, several of these mechanisms may be involved. Table 4 summarises the pathogenetic mechanisms which have been documented during parvovirus B19 infection. B19 acquisition is usually by the respiratory route via aerosol droplet transmission from an acutely infected patient [75] , however, B19 virus may also be transmitted parenterally by infected blood and blood products [74] . Initially, the virus is thought to multiply in the throat, leading to viremia on day 6, with infection of erythroblasts in the bone marrow [75, 76] . Local viral replication is important in most clinical manifestations, except arthralgia, as virus has not been isolated from affected joints. The nonstructural protein (NS1) has been shown to be cytotoxic and NS1 cytotoxicity is thought to account for thrombocytopenia and leucopenia occurring during B19 infection [72] . B19 infection of erythroblasts results in apoptotic killing of infected cells and reticulocyte arrest [72, 73] , and this is important in transient aplastic crisis in patients with shortened red cell survival, erythema infectiosum, hydrops fetalis, chronic pure red cell aplasia, and aplastic anemia and other cytopenias, and may also be important in the pathogenesis of acute leukemia. Specific anti-B19IgG is produced from day 16 and this coincides with appearance of erythema infectiosum and arthralgia [75, 76] , which are thought to be mediated by immune complex deposition, at least in part. Appearance of serum anti-B19 IgG controls the infection, allowing recovery of erythroid cell production [74] .
A variety of autoantibodies are produced during acute B19 infection, including rheumatoid factor, antinuclear antibody, anti-keratin and anti-collagen II antibodies [84] , and antiphospholipid antibody which has the same specificity as that produced in systemic lupus erythematosus [85] .
Various class I and II HLA alleles are associated with occurrence of symptoms (principally arthralgia and rash) during parvovirus B19 infection. These were HLA-B49 and HLA-DRB1*01, *04, *07, *15 and *16 alleles [78, 89] .
In all symptomatic B19-infected subjects who carried the above HLA alleles, there was marked release of various cytokines, including TNF-α, IFN-γ, IL-6, granulocyte-macrophage colony stimulating factor (GM-CSF) and chemokine (C-C motif) ligand 2 (CCL2), and low levels of IL-10 [101, 102] . The B19 NS1 protein upregulates IL-6 in hemopoietic and endothelial cells, and this is mediated by the NF-KB site in the IL-6 promoter [81] .
In addition, in the setting of symptomatic B19 infection, production of antibody to the B19 nonstructural protein was associated with the IL-10 -819/-592*TA haplotype which mediates low IL-10 transcription [103] .
Following acute infection, B19 virus persists in many different tissues, including skin, bone marrow, synovium, and liver, and it is believed that this is a life long phenomenon [104] . The possibility that the B19 genome may integrate into the human genome has been investigated, and although this has not been confirmed to occur in a similar fashion tothe integration of the related parvovirus, adeno-associated virus, the human genome does exhibit short footprints of the B19 genome in multiple human genes, the significance of which remains unclear [105] .
It has recently been shown that a particular pattern of DNA methylation among a subset of cancer genes was associated with a history of parvovirus B19 infection as detected by serum anti-B19 IgG but not anti-B19 IgM [100] . This finding suggests that B19 virus infection may drive specific DNA methylation patterns in susceptible B precursor cells, thus contributing to the leukemogenic potential of these cells, and these changes may be retained even after control of the infection [100] .
Parvovirus B19 as a candidate viral trigger in the pathogenesis of acute leukemia
We believe that parvovirus B19 is involved in the pathogenesis of a subset of cases of acute leukemia, and that B19 virus is one of a number of viral triggers. There are various features of parvovirus B19 which make it a candidate trigger infection in the pathogenesis of acute leukemia. The majority of the population becomes infected early in life in both developed and developing worlds, and so the possibility of delayed infection exists for B19 virus, as has been proposed as a possible mechanism in the pathogenesis of acute childhood leukemia [47] . Interestingly, in studies of B19 infection in childhood leukemia from Mansoura, Egypt, B19 seroprevalence of the normal controls was zero [39, 46] and 10% [40], respectively, which was much lower than B19 seroprevalence in cases of acute childhood leukemia, where it ranged from 40%-45%[39, 40, 46] . The reasons for this apparent delay in occurrence of B19 infection during childhoodin these studies deservefurther attention.
B19 virus is erythrotropic and primarily targets erythroblasts in the bone marrow. However, it is also able to infect various other cell types. B19 infection may directly result in aplastic crisis in patients with shortened red cell survival, and this aplastic crisis has been shown to be a prodrome of ALL in 2% of patients [68, 69] . There are 7 case reports in the literature of B19-associated aplastic anemia, occurring several months prior to the onset of acute leukemia [27] [28] [29] [30] [31] [32] [33] and the clinical course of these cases is summarized in Table 2 .
Symptomatic B19 infection has been shown to be associated with HLA-B49 and HLA-DRB1*01, *04, *07, *15 and *16 alleles [78, 89] . All symptomatic parvovirus-associated HLA-DRB1 molecules carry a neutrallycharged glutamine at position 10 and a positively charged lysine at position 12 of the first hypervariable region (HVR), conferring a net postive charge to this region.HLA-DRB1 molecules with a positively charged firstHVR, include *01, *04, *07, *09, *15 and *16. These associations were demonstrated for both males and females. HLA-B49
[63] and the above HLA-DRB1 molecules with a positive charge in the first HVR, have been associated with development of childhood ALL [57] [58] [59] 63] . In fourpublished cases of B19 infection present at the time of diagnosis of acute childhood leukemia, each patient carried at least one HLA-DRB1 allele with a positive charge in the first HVR [26] . Table 5 shows the net charge in this first HVR for all HLA-DRB1 molecules, and relates this to known class II associations in acute leukemia, symptomatic parvovirus B19 infection and B19-associated acute leukemia.
Acute symptomatic B19 infection has been associated with raised circulating levels of TNF-α, IFN-γ, IL-6, GM-CSF and CCL2, and low levels of IL-10; these pro-inflammatory cytokines remain at elevated levels for up to 3 years following the time of acute infection [101, 102] . Proinflammatory cytokines have been shown to be elevated during the prodrome and onset of acute childhood leukemia, and ALL cells express multiple proinflammatory cytokine receptors. In addition, interleukin-10 secretion is severely deficient in children who grow up to develop leukemia [65] . Development of antibody to the parvovirus B19 nonstructural protein, which is associated with more severe courses of infection, has been associated with the IL-10 -819/-592*TA haplotype which mediates low IL-10 transcription [103] . This is consistent with a heightened immune response in a subset of parvovirus infected persons with particular genetic determinants, and this may also be important in the putative role for parvovirus B19 in the pathogenesis of acute leukemia.
Perspective: viral causes of cancer
Several viruses have been shown to cause human cancer and these are therefore known as oncoviruses. These include Epstein-Barr virus, hepatitis B virus, hepatitis C virus, human T-cell lymphotropic virus, human papillomaviruses, Kaposi´s sarcoma-associated herpesvirus (human herpesvirus 8) and Merkel cell polyomavirus (Table 6) Indirect viral oncogenicity involves chronic non-specific inflammation occurring over decades following acute infection [106, 107] .
Members of the Parvoviridae have a DNA genome and persist indefinitely following acute infection which may or may not be manifested clinically. Parvovirus B19 persists in many different erythroid and non-erythroid human tissues following acute infection, including bone marrow, colon, heart, skin, liver, lymphoid, synovial, testicular and thyroid tissues. However, the mode of persistence of B19 virus is not yet fully understood. The B19 NS1 protein has been shown to upregulate transcription of both IL-6 [81] and TNF-α [108] , and an increased inflammatory response has been demonstrated in some of the above tissues in association with expression of either B19 mRNA or proteins [109] .
Therefore, there are certain aspects of the life cycle of parvovirus B19 which could fit with those of an oncovirus. However, certain parvoviruses, such as the rat parvovirus H-1,have been shown to be oncolytic in humans [110] . Rat parvovirus H-1 (ParvOryx) is currently undergoing clinical trials as a treatment for human glioblastoma multiforme [111] .
Conclusions
Parvovirus B19 infection may complicate the clinical course of acute leukemia by opportunistic infection which may be acquired exogenously or represent reactivation of latent B19 virus. However, acute B19 infection may precede a diagnosis of acute leukemia by up to 180 days, and in some cases is associated with aplastic crisis, which is already recognized to precede development of acute leukemia in a small percentage of cases. B19 virus is a recognized cause of aplasia, the pathogenesis of which is by direct infection of erythroblasts and B19- . However, despite this interesting association, the nucleic acid prevalences of Epstein-Barr virus, cytomegalovirus and human herpesvirus 6 were found to be 14%, 19%, and 9%, respectively [116] , which was taken as evidence against the involvement of these infectious agents in acute leukemia. However, it is difficult to assign pathogenetic significance to the presence of a virus which persists following the acute phase, because the timing of the acute infection and its consequences are unknown at the time of testing.
These authors believe that each case of acute leukemia may be triggered by one of several viruses, including parvovirus B19, and that to identify which virus infection is responsible for a particular case of acute leukemia, it would be necessary to study very large population cohorts, in order to identify the timing of seroconversion to particular viruses occurring contemporaneous with the diagnosis of different types of acute leukemia.
We believe that the current management of parvovirus B19 infections is probably adequate although awareness of the possibility that B19 infection may precede or be contemporaneous with diagnosis of acute leukemia could certainly be improved. 
Figure 1 Legend
A model of the time course and important events in the pathogenesis of parvovirus B19-associated childhood acute lymphoblastic leukemia (ALL).
Initiating mutations occur at a frequency of approximately 1% of normal live births, and among these a second activating mutation occurring after birth in the same cell that harbors the initiating mutation is rare, occurring only in those with an increased potential to react vigorously to early life infections, who have also had a reduced level of exposure to early life infections. According to this model, infection occurs and hematopoiesis is suppressed, allowing the selective outgrowth of pre-leukemic clones, one of which acquires the activating mutation, and with rapid proliferation, develops into ALL. In this model, the infection is by parvovirus B19, which is known to cause reticulocyte arrest and aplastic anemia, and in some individuals, to elicit a vigorous immune response with the potential to further suppress hematopoiesis by the action of cytokines. This figure was adapted from Figure 2 of the review of Greaves [1] and Figure 3 of the review of Wiemels [67] . *TAC = transient aplastic crisis; EI = erythema infectiosum; PRCA = pure red cell aplasia. †Local B19 replication occurs primarily in the erythroblasts, but also occurs in macrophages, myeloid cells, lymphocytes, hepatocytes, and dendritic epidermal and endothelial cells. **Erythroblast apoptosis, mediated by the NS1 protein, occurs in TAC, EI, and hydrops fetalis and probably also in PRCA and aplastic anaemia/cytopenias. ‡B19 NS1 cytotoxicity is thought to account for haematological abnormalities in EI and cytopenias and possibly for arthralgia/arthritis. ¶Immune complex deposition is thought to account for the rash of EI, arthralgia, peripheral neuropathy and may contribute to other B19 associated skin rashes and vasculitis.
† †Anti-B19 VP1 IgG cross reacts with collagen II and keratin, which may be significant in the pathogenesis of arthritis and skin pathology, respectively. Antiphospholipid antibodies occur after B19 infection and may be important in the pathogenesis of autoimmunity. §HLA-B49 and HLA-DRB1*01, *04, *07, *15 and *16 have been shown to be linked with symptomatic B19 infection. ‡ ‡Upregulation of human IL6, mediated by the NS1 protein, may be important in aplastic anaemia/cytopenias and B19 associated arthritis, and skin rashes. ¶ ¶Persistence of B19 is important in PRCA, may be important in B19 associated skin rashes, arthritis, CFS, RA, SLE, and vasculitis. EYSTS -n n n n -*0901 † (rare allele) KQDKF + n -+ n + 57 *1001 EEVKF --n + n -*1101 EYSTS -n n n n -*1301 EYSTS -n n n n -*1501 WQPKR n n n + + + 58,59 89 26 *1601 WQPKR n n n + + + 58,59 89 26 *n, neutral † HLA-DRB4 is one of the expressed HLA loci, which exists only on haplotypes possessing HLA-DRB1*04, *07, and *09
